Cargando…

Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study

Hyperprolactinemia is a prevalent endocrine disorder presented in patients with non-functional pituitary adenomas (NFPAs). However, the mechanism involved in hyperprolactinemia in NFPA is not fully illustrated. The current study aims to investigate predictors for hyperprolactinemia in NFPA via analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Liang, Yin, Senlin, Hu, Yu, Chen, Cheng, Jiang, Yong, Yu, Yang, Ma, Weichao, Wang, Zeming, Jiang, Shu, Zhou, Peizhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544428/
https://www.ncbi.nlm.nih.gov/pubmed/33031334
http://dx.doi.org/10.1097/MD.0000000000022673
_version_ 1783591852101861376
author Lyu, Liang
Yin, Senlin
Hu, Yu
Chen, Cheng
Jiang, Yong
Yu, Yang
Ma, Weichao
Wang, Zeming
Jiang, Shu
Zhou, Peizhi
author_facet Lyu, Liang
Yin, Senlin
Hu, Yu
Chen, Cheng
Jiang, Yong
Yu, Yang
Ma, Weichao
Wang, Zeming
Jiang, Shu
Zhou, Peizhi
author_sort Lyu, Liang
collection PubMed
description Hyperprolactinemia is a prevalent endocrine disorder presented in patients with non-functional pituitary adenomas (NFPAs). However, the mechanism involved in hyperprolactinemia in NFPA is not fully illustrated. The current study aims to investigate predictors for hyperprolactinemia in NFPA via analyzing relevant clinical features. Thus, in this study, a cohort of 214 cases with integrated medical records was retrospectively analyzed concerning clinical, pathological, and endocrinological studies before and after surgery. Hyperprolactinemia happened in 93 cases (43.5%). Women (adjust odds ratio [OR] = 3.093; P < .01), age of patients (adjust OR = 0.951; P < .01), and serum free tetraiodothyronine (FT4) level (adjust OR = 0.882; P = .02) were independent predictors for developing preoperative hyperprolactinemia. Tumor size and hypopituitarism had no impact on hyperprolactinemia. During a median follow-up of 43.5 (range, 22–80) months, 83.9% patients with preoperative hyperprolactinemia experienced prolactin (PRL) normalization. Preoperative PRL level (adjusted OR = 1.741, P = .03) was the exclusive predictor for PRL normalization after adjusting for tumor volume, preoperative serum FT4 concentration, and postoperative residual. The PRL normalization rate of patients with lower PRL level (<2.35-fold upper limit of normal range) was 95.2% and decreased to 65.5% for patients with higher PRL level. In conclusion, our results suggest existence of potentially alternative mechanisms underlying hyperprolactinemia in NFPAs, like the discrepancy of sex and age and the negative feedback of FT4. Preoperative PRL is a predictor for postoperative PRL normalization, which is of clinically relevant for postoperative management of NFPAs.
format Online
Article
Text
id pubmed-7544428
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75444282020-10-30 Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study Lyu, Liang Yin, Senlin Hu, Yu Chen, Cheng Jiang, Yong Yu, Yang Ma, Weichao Wang, Zeming Jiang, Shu Zhou, Peizhi Medicine (Baltimore) 7100 Hyperprolactinemia is a prevalent endocrine disorder presented in patients with non-functional pituitary adenomas (NFPAs). However, the mechanism involved in hyperprolactinemia in NFPA is not fully illustrated. The current study aims to investigate predictors for hyperprolactinemia in NFPA via analyzing relevant clinical features. Thus, in this study, a cohort of 214 cases with integrated medical records was retrospectively analyzed concerning clinical, pathological, and endocrinological studies before and after surgery. Hyperprolactinemia happened in 93 cases (43.5%). Women (adjust odds ratio [OR] = 3.093; P < .01), age of patients (adjust OR = 0.951; P < .01), and serum free tetraiodothyronine (FT4) level (adjust OR = 0.882; P = .02) were independent predictors for developing preoperative hyperprolactinemia. Tumor size and hypopituitarism had no impact on hyperprolactinemia. During a median follow-up of 43.5 (range, 22–80) months, 83.9% patients with preoperative hyperprolactinemia experienced prolactin (PRL) normalization. Preoperative PRL level (adjusted OR = 1.741, P = .03) was the exclusive predictor for PRL normalization after adjusting for tumor volume, preoperative serum FT4 concentration, and postoperative residual. The PRL normalization rate of patients with lower PRL level (<2.35-fold upper limit of normal range) was 95.2% and decreased to 65.5% for patients with higher PRL level. In conclusion, our results suggest existence of potentially alternative mechanisms underlying hyperprolactinemia in NFPAs, like the discrepancy of sex and age and the negative feedback of FT4. Preoperative PRL is a predictor for postoperative PRL normalization, which is of clinically relevant for postoperative management of NFPAs. Lippincott Williams & Wilkins 2020-10-09 /pmc/articles/PMC7544428/ /pubmed/33031334 http://dx.doi.org/10.1097/MD.0000000000022673 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 7100
Lyu, Liang
Yin, Senlin
Hu, Yu
Chen, Cheng
Jiang, Yong
Yu, Yang
Ma, Weichao
Wang, Zeming
Jiang, Shu
Zhou, Peizhi
Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study
title Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study
title_full Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study
title_fullStr Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study
title_full_unstemmed Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study
title_short Hyperprolactinemia in clinical non-functional pituitary macroadenomas: A STROBE-compliant study
title_sort hyperprolactinemia in clinical non-functional pituitary macroadenomas: a strobe-compliant study
topic 7100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544428/
https://www.ncbi.nlm.nih.gov/pubmed/33031334
http://dx.doi.org/10.1097/MD.0000000000022673
work_keys_str_mv AT lyuliang hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT yinsenlin hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT huyu hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT chencheng hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT jiangyong hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT yuyang hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT maweichao hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT wangzeming hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT jiangshu hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy
AT zhoupeizhi hyperprolactinemiainclinicalnonfunctionalpituitarymacroadenomasastrobecompliantstudy